Whole-course C-reactive protein (hsCRP+CRP) assay kit (quantum dot immunochromatographic method)
CRP is one of the predictive factors for cardiovascular disease risk in healthy individuals and patients with coronary artery disease.

C-reactive protein (CRP) is an acute-phase protein with a pentameric structure, exhibiting excellent stability and precision. It serves as a non-specific biomarker for inflammation and tissue injury. In humans, CRP is composed of five identical non-glycosylated polypeptide subunits, each consisting of 206 amino acid residues and two calcium ion-binding sites.
CRP is synthesized by hepatocytes and is transcriptionally regulated by several cytokines, such as interleukin (IL)-6, IL-1, tumor necrosis factor, interferon, etc.2. There is also evidence suggesting that CRP may be locally produced in vascular smooth muscle cells (SMCs) and macrophages involved in atherosclerotic lesions. There has been ongoing debate about whether CRP itself is a pathogenic factor in the formation of atherosclerotic thrombi. The available data indicate that pentameric CRP is primarily a biomarker for cardiovascular diseases, rather than a pathogenic factor. This data emphasizes the importance of targeting upstream inflammatory mediators as a potential therapeutic approach for cardiovascular diseases3.
High-sensitivity C-reactive protein (hsCRP)
After systematically evaluating the association between inflammatory markers and cardiovascular disease, the American Heart Association (AHA) and the Centers for Disease Control and Prevention (CDC) recommend high-sensitivity C-reactive protein (hsCRP) as a marker for predicting cardiovascular disease4-6. High-sensitivity CRP (hsCRP) is the same protein as CRP. hsCRP exhibits higher sensitivity and accuracy within the low concentration range of 1-10 mg/L, whereas the detectable range of conventional CRP is generally 10-200 mg/L. This compensates for the limitations of conventional CRP's detection range and enhances the potential risk of cardiovascular disease prediction. The AHA/CDC guidelines for cardiovascular disease risk assessment are as follows: hsCRP level <1 mg/L, low risk; 1 mg/L < hsCRP level <3 mg/L, moderate risk; hsCRP level >3 mg/L, high risk3,6.

References
1.Pepys M B, Hirschfield G M. C-reactive protein: a critical update.[J]. Journal of Clinical Investigation, 2003, 111(12):1805-12.
2.Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture.[J]. Arteriosclerosis Thrombosis & Vascular Biology, 2007, 27(1):15-26.
3.Ridker P M. A Test in Context, : High-Sensitivity C-Reactive Protein[J]. Journal of the American College of Cardiology, 2016, 67(6):712.
4.Sang W, Dae J, Park, et al. Evaluation of fluorescence hs-CRP immunoassay for point-of-care testing[J]. Clinica chimica acta; international journal of clinical chemistry, 2005, 356(1-2):172.
5.Paz J C, West M P. Acute Care Handbook for Physical Therapists (Fourth Edition)[M]. 2013.
6.Pearson T A, Mensah G A, Alexander R W, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association[J]. Circulation, 2003, 107(3): 499-511.